Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pharmacia and Upjohn Clear all
Terminated Phase 2 Interventional

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

NCT00002420
View directory record Official record
Conditions
HIV Infections
Interventions
Emivirine, Hydroxyurea, Delavirdine mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Not applicable Interventional

Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E

NCT00002094
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

NCT00318903
View directory record Official record
Conditions
Esophageal Cancer, Cancer of the Esophagus, Esophagus Cancer, Esophageal Neoplasm, Cancer of Esophagus
Interventions
Irinotecan (drug), Taxotere (drug), Radiotherapy (procedure), Esophagectomy (procedure)
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 6, 2026, 10:21 AM EDT
Terminated Phase 1 Interventional

Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer

NCT00177853
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
celecoxib, irinotecan, concurrent radiotherapy
Drug · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2010 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Phase 1 Interventional

Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

NCT00002087
View directory record Official record
Conditions
HIV Infections
Interventions
Alvircept sudotox
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Not applicable Interventional

A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00002400
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Delavirdine mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Not applicable Interventional

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

NCT00002236
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Delavirdine mesylate, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

Irinotecan in Treating Patients With Esophageal or Stomach Cancer

NCT00003748
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
25
States / cities
Bakersfield, California • Fullerton, California • Inglewood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

NCT00193596
View directory record Official record
Conditions
Neoplasms, Unknown Primary
Interventions
Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
31
States / cities
Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 28 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

NCT00201747
View directory record Official record
Conditions
Esophageal Cancer, Esophagus Cancer, Cancer of Stomach, Stomach Cancer
Interventions
CPT-11, Mitomycin C
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine

NCT00002312
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Not applicable Interventional

A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

NCT00002401
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Delavirdine mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

NCT00002123
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Didanosine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
83
States / cities
Birmingham, Alabama • Berkeley, California • Fresno, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

NCT00002124
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
87
States / cities
Birmingham, Alabama • Berkeley, California • Clovis, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

NCT00002210
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
1 Month to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

NCT00002322
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

NCT00002211
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Delavirdine mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:21 AM EDT